274 lines
No EOL
94 KiB
XML
274 lines
No EOL
94 KiB
XML
<?xml version="1.0" encoding="utf-8"?>
|
||
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
||
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
||
|
||
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
||
<!-- AppResources meta begin -->
|
||
<meta name="paf-app-resources" content="" />
|
||
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
||
|
||
<!-- AppResources meta end -->
|
||
|
||
<!-- TemplateResources meta begin -->
|
||
<meta name="paf_template" content="" />
|
||
|
||
<!-- TemplateResources meta end -->
|
||
|
||
<!-- Logger begin -->
|
||
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548406" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="printable" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548406/?report=printable" /><meta name="ncbi_app" content="bookshelf" />
|
||
<!-- Logger end -->
|
||
|
||
<title>Methimazole - LiverTox - NCBI Bookshelf</title>
|
||
|
||
<!-- AppResources external_resources begin -->
|
||
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
||
|
||
<!-- AppResources external_resources end -->
|
||
|
||
<!-- Page meta begin -->
|
||
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Methimazole" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/01/22" /><meta name="citation_pmid" content="31643725" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548406/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Methimazole" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/01/22" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548406/" /><meta name="description" content="Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course." /><meta name="og:title" content="Methimazole" /><meta name="og:type" content="book" /><meta name="og:description" content="Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548406/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/Methimazole/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548406/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} </style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script>
|
||
|
||
<!-- Page meta end -->
|
||
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B70CD7D7DA9210000000000C400A0.m_5" />
|
||
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3984801/12930/3964959.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
||
<body class="book-part">
|
||
<div class="grid no_max_width">
|
||
<div class="col twelve_col nomargin shadow">
|
||
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
||
<div class="sysmessages">
|
||
<noscript>
|
||
<p class="nojs">
|
||
<strong>Warning:</strong>
|
||
The NCBI web site requires JavaScript to function.
|
||
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
||
</p>
|
||
</noscript>
|
||
</div>
|
||
<!--/.sysmessage-->
|
||
<div class="wrap">
|
||
<div class="page">
|
||
<div class="top">
|
||
|
||
<div class="header">
|
||
|
||
|
||
</div>
|
||
|
||
|
||
|
||
<!--<component id="Page" label="headcontent"/>-->
|
||
|
||
</div>
|
||
<div class="content">
|
||
<!-- site messages -->
|
||
<div class="container content">
|
||
<div class="document">
|
||
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div></div></div>
|
||
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548406_"><span class="title" itemprop="name">Methimazole</span></h1><p class="small">Last Update: <span itemprop="dateModified">January 22, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="Methimazole.OVERVIEW"><h2 id="_Methimazole_OVERVIEW_">OVERVIEW</h2><div id="Methimazole.Introduction"><h3>Introduction</h3><p>Methimazole is an antithyroid medication which is now considered the first line agent for medical therapy of hyperthyroidism and Graves disease. Methimazole has been linked to serum aminotransferase elevations during therapy as well as to a clinically apparent, idiosyncratic liver injury that is typically cholestatic and self-limited in course.</p></div><div id="Methimazole.Background"><h3>Background</h3><p>Methimazole (meth im' a zole), which is also known as thiamazole, is a thioamide and a thyroid hormone antagonist which acts by inhibiting the incorporation of iodine into tyrosyl residues of thyroglobulin and, thus, lowering thyroid hormone levels. Methimazole resembles propylthiouracil both in chemical structure and activity. Methimazole was introduced into use in 1954 and is still widely used for the temporary amelioration of hyperthyroidism in Graves disease, particularly in patients with mild or self-limited hyperthyroidism or who wish to avoid thyroidectomy or radiation therapy. Because of the hepatotoxicity of propylthiouracil which can be fatal, methimazole is now considered the first line treatment for hyperthyroidism when there is a need to avoid surgery or radioiodine therapy. Methimazole is available in generic forms and under the brand name of Tapazole as tablets of 5 and 10 mg. The usual dose in adults is 15 to 60 mg daily in three divided doses until the patient is euthyroid, followed by a maintenance dose of 5 to 15 mg daily. Common side effects include gastrointestinal upset, headache, drowsiness, arthralgias, paresthesias, hair loss and rash. Rare complications of methimazole (<1%) include agranulocytosis, aplastic anemia, nephritis and hepatitis.</p></div><div id="Methimazole.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Methimazole has been associated with transient, asymptomatic elevations in serum aminotransferase levels, typically during the first 3 months after starting during high dose, induction therapy. These elevations are rarely clinically significant and usually resolve even with continuation of therapy. Methimazole is also capable of causing clinically apparent, idiosyncratic liver injury. The onset of hepatotoxicity is usually within 2 to 12 weeks of starting and the pattern of enzyme elevations is typically cholestatic or mixed, although hepatocellular patterns have also been described. The cholestatic hepatitis caused by methimazole can be prolonged, but fatalities are rare and symptoms and jaundice usually clear within 2 to 8 weeks of stopping therapy. Rare instances of prolonged cholestasis have been described, but no instance of vanishing bile duct syndrome.</p><p>Complicating the assessment of the role of methimazole or propylthiouracil in causing liver injury is the fact that hyperthyroidism by itself can cause liver test abnormalities and even jaundice. Indeed, more than half of patients with untreated hyperthyroidism have serum enzyme abnormalities (usually less than 5 times the upper limit of the normal range) and a small proportion are jaundiced and present with cholestatic hepatitis. The liver test elevations are most frequent in patients with high output heart failure. The abnormalities resolve rapidly with treatment of hyperthyroidism either with surgery, radioactive iodine or antithyroid medications.</p><p>Likelihood score: A (well known but rare cause of clinically apparent liver injury).</p></div><div id="Methimazole.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The mechanism by which methimazole causes acute liver injury is unknown, but is likely due to an immunological reaction to a metabolic product of its metabolism.</p></div><div id="Methimazole.Outcome_and_Management"><h3>Outcome and Management</h3><p>The severity of methimazole induced liver injury varies from mild, transient serum aminotransferase elevations to moderately severe cholestatic hepatitis. Fatal cases are rare. Some cases have features of autoimmunity or immunoallergic hepatitis and have been treated with corticosteroids, but without proven evidence of benefit. Recovery is usually rapid once methimazole is stopped, and the first priority should be immediate discontinuation of antithyroid therapy at the first sign of clinically apparent liver disease. The presence of hyperthyroidism may play a role in worsening liver function, and temporary management with beta-blockers or other approaches may be necessary even during the course of the acute liver injury. In several instances, patients with methimazole induced liver injury have been switched to propylthiouracil without evidence of recurrence, but in at least one case, recurrent jaundice appeared. In severe cases, however, more definitive therapy of the hyperthyroidism with radioactive iodide or surgery may be more appropriate.</p><p>Drug Class: <a href="/books/n/livertox/Antithyroid/">Antithyroid Agents</a></p><p>Other Drugs in the Class: <a href="/books/n/livertox/Propylthiouracil/">Propylthiouracil</a></p></div></div><div id="Methimazole.CASE_REPORT"><h2 id="_Methimazole_CASE_REPORT_">CASE REPORT</h2><div id="Methimazole.Case_1_Mixed_cholestatichepa"><h3>Case 1. Mixed cholestatic-hepatocellular injury due to methimazole.(<a class="bk_pop" href="#Methimazole.REF.1">1</a>)</h3><p>A 43 year old woman with Graves disease developed pruritus and jaundice one month after starting therapy with methimazole (10 mg) and propranolol (20 mg), both given three times daily. She did not have abdominal pain, nausea, fever or rash. She continued taking methimazole for 4 days after the appearance of jaundice and presented to the hospital two weeks later because of persistent jaundice and pruritus. She had no history of liver disease or alcohol abuse and no risk factors for viral hepatitis. She had been clinically hyperthyroid with palpitations, tremor and elevated serum T4 levels [30.7 μg/dL] before therapy and routine liver tests were mildly abnormal (Table). On presentation, she was jaundiced but had no signs of chronic liver disease. Laboratory testing showed elevations in serum direct and total bilirubin and a cholestatic pattern of enzyme elevations. CT imaging of the abdomen showed no evidence of biliary obstruction. Tests for hepatitis A, B and C and autoantibodies were negative. Propranolol therapy was restarted but methimazole was held. She improved and jaundice resolved within 4 weeks and other liver test abnormalities within 8 weeks. After recovery from the liver injury, her hyperthyroidism was treated successfully with radioactive iodine.</p><div id="Methimazole.Key_Points"><h4>Key Points</h4><div id="Methimazole.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548406/table/Methimazole.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Methimazole.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_Methimazole.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_Methimazole.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methimazole (30 mg daily)</td></tr><tr><th id="hd_b_Methimazole.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_Methimazole.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cholestatic (R=0.6)</td></tr><tr><th id="hd_b_Methimazole.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_Methimazole.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">3+ (jaundice and hospitalization)</td></tr><tr><th id="hd_b_Methimazole.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Latency:</th><td headers="hd_b_Methimazole.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1 month</td></tr><tr><th id="hd_b_Methimazole.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_Methimazole.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">2 months</td></tr><tr><th id="hd_b_Methimazole.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_Methimazole.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Amlodipine, propranolol (both continued)</td></tr></tbody></table></div></div></div><div id="Methimazole.Laboratory_Values"><h4>Laboratory Values</h4><div id="Methimazole.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548406/table/Methimazole.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Methimazole.Td_lrgtbl__"><table><thead><tr><th id="hd_h_Methimazole.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Starting</th><th id="hd_h_Methimazole.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Time After<br />Stopping</th><th id="hd_h_Methimazole.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">ALT<br />(U/L)</th><th id="hd_h_Methimazole.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_Methimazole.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Bilirubin<br />(mg/dL)</th><th id="hd_h_Methimazole.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Other</th></tr></thead><tbody><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pre</td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">134</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">201</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">6 weeks</td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">14 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">104</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">289</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">16.7</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Admission</td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">15 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">91</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">264</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">14.9</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">16 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">13.3</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">18 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">130</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">233</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">12.6</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">7 weeks</td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">20 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">269</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">235</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11.4</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">22 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">248</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">209</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">8.8</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Discharge</td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">26 days</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">151</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">150</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4.7</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">12 weeks</td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">8 weeks</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">63</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">154</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1.6</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5 months</td><td headers="hd_h_Methimazole.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">4 months</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">66</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">111</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.6</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_Methimazole.Td_1_1_1_1 hd_h_Methimazole.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;">
|
||
<b>Normal Values</b>
|
||
</td><td headers="hd_h_Methimazole.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<b><75</b>
|
||
</td><td headers="hd_h_Methimazole.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<b><116</b>
|
||
</td><td headers="hd_h_Methimazole.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">
|
||
<b><1.2</b>
|
||
</td><td headers="hd_h_Methimazole.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div></div></div><div id="Methimazole.Comment"><h4>Comment</h4><p>Typical cholestatic hepatitis arising one month after starting therapy with methimazole. The patient was ill for almost two months but recovery was otherwise uncomplicated.</p></div></div></div><div id="Methimazole.PRODUCT_INFORMATION"><h2 id="_Methimazole_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p>
|
||
<b>REPRESENTATIVE TRADE NAMES</b>
|
||
</p><p>Methimazole – Tapazole®</p><p>
|
||
<b>DRUG CLASS</b>
|
||
</p><p>Antithyroid Agents</p><p>
|
||
<a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=METHIMAZOLE" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">COMPLETE LABELING</a>
|
||
</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="Methimazole.CHEMICAL_FORMULA_AND_STRUCTU"><h2 id="_Methimazole_CHEMICAL_FORMULA_AND_STRUCTU_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="Methimazole.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548406/table/Methimazole.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__Methimazole.Te_lrgtbl__"><table><tbody><tr><th id="hd_b_Methimazole.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_b_Methimazole.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_b_Methimazole.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_b_Methimazole.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr><tr><td headers="hd_b_Methimazole.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methimazole</td><td headers="hd_b_Methimazole.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970546" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem">60-56-0</a>
|
||
</td><td headers="hd_b_Methimazole.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C4-H6-N2-S</td><td headers="hd_b_Methimazole.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
||
<a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970546" title="View this structure in PubChem" class="img_link" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&sid=134970546" alt="image 134970546 in the ncbi pubchem database" /></a>
|
||
</td></tr></tbody></table></div></div></div><div id="Methimazole.CITED_REFERENCE"><h2 id="_Methimazole_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="Methimazole.REF.1">Mikhail NE. Methimazole-induced cholestatic jaundice. <span><span class="ref-journal">South Med J. </span>2004;<span class="ref-vol">97</span>:178–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14982270" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14982270</span></a>]</div></dd></dl></div><div id="Methimazole.ANNOTATED_BIBLIOGRAPHY"><h2 id="_Methimazole_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 10 February 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="Methimazole.REF.zimmerman.1999">Zimmerman HJ. Antithyroid drugs. Hormonal derivatives and related drugs. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 579-81.<div><i>(Expert review of hepatotoxicity of antithyroid medications published in 1999; mentions 35 recorded cases of jaundice attributed to propylthiouracil [usually hepatocellular] and 15 to methimazole [usually cholestatic]).</i></div></div></li><li><div class="bk_ref" id="Methimazole.REF.chitturi.2013">Chitturi S, Farrell GC. Antithyroid drugs. Adverse effects of hormones and hormone antagonists on the liver. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 614-5.<div><i>(Review of hepatotoxicity of antithyroid agents mentions that methimazole typically causes a cholestatic hepatitis arising within 2-12 weeks of starting and with "uneventful recovery").</i></div></div></li><li><div class="bk_ref" id="Methimazole.REF.brent.2018">Brent GA, Koenig RJ. Thyroid and anti-thyroid drugs. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp.787-802.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="Methimazole.REF.specht.1952.1010">Specht NW, Boehme EJ. Death due to agranulocytosis induced by methimazole therapy. <span><span class="ref-journal">JAMA. </span>1952;<span class="ref-vol">149</span>:1010–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14938092" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14938092</span></a>]<div>
|
||
<i>(67 year old woman developed fever 4 weeks after starting methimazole with agranulocytosis and jaundice, dying within 1-2 days; liver at autopsy showing “central congestion”).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.rosenbaum.1953.27">Rosenbaum H, Reveno WS. Agranulocytosis and toxic hepatitis from methimazole. <span><span class="ref-journal">JAMA. </span>1953;<span class="ref-vol">152</span>:27.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13034518" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13034518</span></a>]<div>
|
||
<i>(62 year old woman developed jaundice 7 weeks after starting methimazole followed by agranulocytosis, resolving rapidly with stopping methimazole; had tolerated propylthiouracil).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.shipp.1955.701">Shipp JC. Jaundice during methimazole (‘Tapazole’) administration. <span><span class="ref-journal">Ann Intern Med. </span>1955;<span class="ref-vol">42</span>:701–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14350490" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14350490</span></a>]<div>
|
||
<i>(63 year old developed pruritus followed by jaundice 2 weeks after starting methimazole [bilirubin 8.7 mg/dL, Alk P 3 times ULN], with subsequent worsening of jaundice and agranulocytosis responding to antibiotics; resolution of jaundice in 10 weeks).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.tennenbaum.1962.306">Tennenbaum JI, Dreskin OH. Toxic hepatitis during treatment with methimazole (Tapazole). Report of a case with apparent recovery. <span><span class="ref-journal">Ohio Med J. </span>1962;<span class="ref-vol">58</span>:306–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/13920238" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13920238</span></a>]<div>
|
||
<i>(38 year old woman developed rash, jaundice and pruritus ~4 weeks after starting methimazole [bilirubin 6.2 mg/dL, ALT 545 U/L, Alk P ~2 times ULN, 12% eosinophils], slowly resolving on stopping therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.martinezlopez.1962.84">Martinez-Lopez JI, Greenberg SE, Kling RR. Drug-induced hepatic injury during methimazole therapy. <span><span class="ref-journal">Gastroenterology. </span>1962;<span class="ref-vol">43</span>:84–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14470520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14470520</span></a>]<div>
|
||
<i>(36 year old woman developed jaundice and pruritus 1 month after starting methimazole [bilirubin 18 m/dL, Alk P 3 times ULN, AST 400 U/L, protime 18 sec]; she delayed in stopping methimazole and jaundice persisted for 10 weeks).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.greenberger.1964.840">Greenberger NJ, Milligan FD, DeGroot LJ, Isselbacher KJ. Jaundice and thyrotoxicosis in the absence of congestive heart failure. A study of four cases. <span><span class="ref-journal">Am J Med. </span>1964;<span class="ref-vol">36</span>:840–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14162890" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14162890</span></a>]<div>
|
||
<i>(Description of 4 patients with jaundice and hyperthyroidism with congestive heart failure, but not on therapy and with no other known cause of liver disease [bilirubin 1.3-6.4 mg/dL, Alk P 1-3 times ULN, AST 13-40 U/L], jaundice resolving with successful therapy of hyperthyroidism).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.sambe.1965.69">Sambe K. Liver injury due to drugs. <span><span class="ref-journal">Acta Hepatol (Japan). </span>1965;<span class="ref-vol">6</span>:69.</span><div>
|
||
<i>(Review of pathology of 19 cases of drug induced liver disease, one due to methylthioracil [similar to propylthiouracil, not used in US] and one to mercazol [carbimazole]; little clinical information given).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.becker.1968.1787">Becker CE, Gorden P, Robbins J. Hepatitis from methimazole during adrenal steroid therapy for malignant exophthalmos. <span><span class="ref-journal">JAMA. </span>1968;<span class="ref-vol">26</span>:1787–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4177058" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4177058</span></a>]<div>
|
||
<i>(54 year old woman on corticosteroids for severe exophthalmos developed jaundice 4 weeks after starting methimazole [bilirubin 5.1 mg/dL, ALT 414 U/L, Alk P 1.5 times ULN], switched to propylthiouracil and recovered promptly).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.fischer.1973.1028">Fischer MG, Nayer HR, Miller A. Methimazole-induced jaundice. <span><span class="ref-journal">JAMA. </span>1973;<span class="ref-vol">223</span>:1028–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4739295" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4739295</span></a>]<div>
|
||
<i>(74 year old woman developed jaundice 2 weeks after starting methimazole [bilirubin 13.6 mg/dL, Alk P 270 U/L, ALT 96 U/L], jaundice lasted 2 months after stopping even with prednisone therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.ishizuki.1974.1083">Ishizuki Y. <span><span class="ref-journal">Horumon To Rinsho. </span>1974;<span class="ref-vol">22</span>:1083–5.</span> [2 cases of liver diseases caused by thyroid antagonists] Japanese. [<a href="https://pubmed.ncbi.nlm.nih.gov/4473289" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4473289</span></a>]<div>
|
||
<i>(Two cases, ages 62 and 75 years, had onset of jaundice 3 and 5 weeks after starting antithyroid medications, with prolonged cholestasis in patient in whom methimazole was continued).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.kimura.1982.685">Kimura T, Shindo T. <span><span class="ref-journal">Nippon Naika Gakkai Zasshi. </span>1982;<span class="ref-vol">71</span>:685–91.</span> [A case of insulin autoimmune syndrome with cholestatic hepatitis induced by methimazole and propylthiouracil] Japanese. [<a href="https://pubmed.ncbi.nlm.nih.gov/7130811" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7130811</span></a>]</div></li><li><div class="bk_ref" id="Methimazole.REF.cooper.1984.1353">Cooper DS. Antithyroid drugs. <span><span class="ref-journal">N Engl J Med. </span>1984;<span class="ref-vol">311</span>:1353–62.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/6387489" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6387489</span></a>]<div>
|
||
<i>(Extensive review of mechanism of action, efficacy and safety of propylthiouracil and methimazole in treating hyperthyroidism; side effects occur in 1-5% of patients, including fever, rash, urticaria, transient leucopenia, and arthralgias particularly with higher doses; severe side effects include agranulocytosis, vasculitis, aplastic anemia, thrombocytopenia and nephritic syndrome).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.vitug.1985.229">Vitug AC, Goldman JM. Hepatotoxicity from antithyroid drugs. <span><span class="ref-journal">Horm Res. </span>1985;<span class="ref-vol">21</span>:229–34.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/4007783" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4007783</span></a>]<div>
|
||
<i>(Review of literature identified 29 cases of hepatic injury due to propylthiouracil [n=17], methimazole [n=10] and carbimazole [n=3]; propylthiouracil cases were predominantly hepatocellular with onset in 10 days to 5 months; liver injury from other agents was primarily cholestatic arising in 10 days to 8 weeks).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.schmidt.1986.244">Schmidt G, Boerach G, Mueller KM, Wegener M. Methimazole associated cholestatic liver injury: case report and brief literature review. <span><span class="ref-journal">Hepato-gastroenterol. </span>1986;<span class="ref-vol">33</span>:244–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/3804181" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3804181</span></a>]<div>
|
||
<i>(58 year old woman developed abdominal pain 18 days after starting methimazole [bilirubin 1.2 mg/dL, ALT 93 U/L, Alk P 572 U/L], with improvement on stopping and recurrent rise in Alk P with rechallenge).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.yao.1989.619">Yao JD, Gross JB Jr, Ludwig J, Purnell DC. Cholestatic jaundice in hyperthyroidism. <span><span class="ref-journal">Am J Med. </span>1989;<span class="ref-vol">86</span>:619–20.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2712072" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2712072</span></a>]<div>
|
||
<i>(42 year old man presented with jaundice and weight loss [bilirubin 16.7 rising to 36.0 mg/dL, ALT 76 U/L, Alk P 252 U/L] on no medications, liver biopsy showed intrahepatic cholestasis and he was found to be hyperthyroid, jaundice resolving after radioactive iodine therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.baker.1989.17">Baker B, Shapiro B, Fig LM, Woodbury D, Sisson JC, Beierwaltes WH. Unusual complications of antithyroid drug therapy: four case reports and review of literature. <span><span class="ref-journal">Thyroidology. </span>1989;<span class="ref-vol">1</span>:17–26.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2484903" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2484903</span></a>]<div>
|
||
<i>(Three cases of hepatotoxicity from thyroid medications; 34 year old woman developed jaundice 6 months after starting propylthiouracil [bilirubin 20.6 mg/dL, ALT 957 U/L, Alk P 176 U/L], with delayed withdrawal and slow recovery; 9 year old girl developed jaundice 3 months after starting propylthiouracil [bilirubin 9.0 mg/dL, ALT 1407 U/L, Alk P 848 U/L], resolving rapidly upon stopping; 20 year old woman developed jaundice 8 months after starting methimazole [bilirubin 27 mg/dL, ALT 2040 U/L, Alk P 389 U/L], progressing to hepatic failure and death and autopsy showed massive necrosis).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.werner.1989.716">Werner MC, Romaldini JH, Bromberg N, Werner RS, Farah CS. Adverse effects related to thioamide drugs and their dose regimen. <span><span class="ref-journal">Am J Med Sci. </span>1989;<span class="ref-vol">297</span>:716–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2523194" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2523194</span></a>]<div>
|
||
<i>(Among 389 treated patients with Graves disease, 5 had hepatotoxicity, 4 of 131 [2%] on propylthiouracil and 1 of 258 [0.5%] on methimazole, all recovered; mostly on high dose therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.kang.1990.69">Kang H, Choi JD, Jung IG, Kim DW, Kim TB, Shin HK, et al. A case of methimazole-induced acute hepatic failure in a patient with chronic hepatitis B carrier. <span><span class="ref-journal">Korean J Intern Med. </span>1990;<span class="ref-vol">5</span>:69–73.</span> [<a href="/pmc/articles/PMC4535001/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4535001</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2271514" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2271514</span></a>]<div>
|
||
<i>(43 year old man with HBsAg carrier state developed jaundice 7 months after starting methimazole [bilirubin 5.0 mg/dL, ALT 180 U/L, Alk P 848 U/L, no detectable HBV DNA], developed worsening hepatic failure and died 30 days after admission, autopsy showed cirrhosis with severe cholestasis).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.di_gregorio.1990.75">Di Gregorio C, Ghini F, Rivasi F. Granulomatous hepatitis in a patient receiving methimazole. <span><span class="ref-journal">Ital J Gastroenterol. </span>1990;<span class="ref-vol">22</span>:75–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/2131935" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2131935</span></a>]<div>
|
||
<i>(56 year old woman developed abnormal liver tests 11 years after starting methimazole and not resolving when drug was stopped, biopsy showing active granulomas with giant cells suggestive of sarcoidosis [bilirubin normal, ALT 51-138 U/L, Alk P 484-652 U/L]).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.findor.1991.115">Findor J, Bruch Igartúa E, Sorda J, Jury R. <span><span class="ref-journal">Acta Gastroenterol Latinoam. </span>1991;<span class="ref-vol">21</span>:115–9.</span> [Jaundice caused by methimazole] Spanish. [<a href="https://pubmed.ncbi.nlm.nih.gov/1687933" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1687933</span></a>]</div></li><li><div class="bk_ref" id="Methimazole.REF.sola.1991.193">Sola J, Pardo-Mindán FJ, Zozaya J, Quiroga J, Sangro B, Prieto J. Liver changes in patients with hyperthyroidism. <span><span class="ref-journal">Liver. </span>1991;<span class="ref-vol">11</span>:193–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/1943501" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1943501</span></a>]<div>
|
||
<i>(Four patients with thyrotoxicosis and “cholestasis” [bilirubin 0.8-1.0 mg/dL, Alk P 300-548 U/L, GGT 17-166 U/L], biopsies showing intrahepatic cholestasis).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.peter.1991.75">Peter SA. Propylthiouracil-associated hepatitis. <span><span class="ref-journal">J Natl Med Assoc. </span>1991;<span class="ref-vol">83</span>:75–7.</span> [<a href="/pmc/articles/PMC2627005/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2627005</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/1994070" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1994070</span></a>]<div>
|
||
<i>(43 year old woman developed jaundice 10 weeks after starting propylthiouracil [bilirubin 6.4 mg/dL, AST 926 U/L, Alk P 292 U/L], worsening for 10 days and then resolving within 10 weeks of stopping).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.liaw.1993.424">Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ. Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. <span><span class="ref-journal">Ann Intern Med. </span>1993;<span class="ref-vol">118</span>:424–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8439116" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8439116</span></a>]<div>
|
||
<i>(60 patients with hyperthyroidism and normal baseline ALT levels were monitored on propylthiouracil, 28% developed ALT elevations [40-231 U/L] all within 2 months of starting initial high dosage [300 mg/day], falling to normal with continuation [100 mg/day]; no symptoms, jaundice or Alk P elevations; liver biopsies in 3 patients showed spotty necrosis and ill defined granulomas).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.sadoul.1993.473">Sadoul JL, Canivet B, Freychet P. Toxic hepatitis induced by antithyroid drugs: four cases including one with cross-reactivity between carbimazole and benzylthiouracil. <span><span class="ref-journal">Eur J Med. </span>1993;<span class="ref-vol">2</span>:473–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7504976" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7504976</span></a>]<div>
|
||
<i>(Retrospective analysis of 236 patients with hyperthyroidism treated at one center found 4 cases [1.7%] with hepatotoxicity due to carbimazole; only one with jaundice [bilirubin 3.5 mg/dL, ALT 162 U/L, Alk P 318 U/L], resolution in 4 weeks of stopping; other cases anicteric and associated with drug fever or rash, largely cholestatic enzyme patterns).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.huang.1994.1071">Huang MJ, Li KL, Wei JS, Wu SS, Fan KD, Liaw YF. Sequential liver and bone biochemical changes in hyperthyroidism: prospective controlled follow-up study. <span><span class="ref-journal">Am J Gastroenterol. </span>1994;<span class="ref-vol">89</span>:1071–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7912472" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7912472</span></a>]<div>
|
||
<i>(Prospective study of 95 patients with hyperthyroidism treated with propylthiouracil; 76% had at least one liver test abnormality before therapy, 37% in ALT [peak 169 U/L] and 64% in Alk P [peak 337 U/L]; ALT levels often decreased with treatment, but rose further in 38%, one developing jaundice [ALT 1490 U/L], resolving with stopping therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.mamianetti.1995.693">Mamianetti A, Muñoz A, Ronchetti RD, Maccione E, Poggi U, Mugnolo R, et al. <span><span class="ref-journal">Medicina (B Aires). </span>1995;<span class="ref-vol">55</span>:693–6.</span> [Acquired sideroblastic anemia and cholestasis in a hyperthyroid patient treated with methimazole and atenolol] Spanish. [<a href="https://pubmed.ncbi.nlm.nih.gov/8731582" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8731582</span></a>]<div>
|
||
<i>(62 year old woman developed jaundice and pruritus within 10 days of starting methimazole [bilirubin 16 rising to 39 mg/dL, ALT 65 U/L, Alk P 670 U/L], with prolonged jaundice and sideroblastic anemia, resolving slowly with normal tests 14 months later).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.arab.1995.1083">Arab DM, Malatjalian DA, Rittmaster RS. Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>1995;<span class="ref-vol">80</span>:1083–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/7714072" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7714072</span></a>]<div>
|
||
<i>(48 year old man with hyperthyroidism and mild liver enzyme abnormalities developed jaundice and worsening pruritus 1 month after starting methimazole [bilirubin 30.1 mg/dL, AST 40 U/L, Alk P 475 U/L], improving with stopping methimazole and achieving euthyroidism with radioactive iodide).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.schwab.1996.225">Schwab GP, Wetscher GJ, Vogl W, Redmond E. Methimazole-induced cholestatic liver injury, mimicking sclerosing cholangitis. <span><span class="ref-journal">Langenbecks Arch Chir. </span>1996;<span class="ref-vol">381</span>:225–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/8817448" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8817448</span></a>]<div>
|
||
<i>(68 year old man developed jaundice and pruritus 2 months after starting methimazole [bilirubin 3.1 rising to 12.2 mg/dL, ALT 61 U/L, Alk P 530 U/L], resolving within 3 months of stopping and with thyroidectomy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.deidiker.1996.845">Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: case report and review of the literature. <span><span class="ref-journal">Pediatr Pathol Lab Med. </span>1996;<span class="ref-vol">16</span>:845–52.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9025882" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9025882</span></a>]<div>
|
||
<i>(13 year old girl developed jaundice 4 months after starting propylthiouracil [bilirubin 13.8 mg/dL, ALT 1716 U/L, Alk P not given, ANA 1:20], worsening and undergoing liver transplantation within 7 days, but dying postoperatively, explant showing massive necrosis and collapse).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.g_rlek.1997.180">Gürlek A, Cobankara V, Bayraktar M. Liver tests in hyperthyroidism: effect of antithyroid therapy. <span><span class="ref-journal">J Clin Gastroenterol. </span>1997;<span class="ref-vol">24</span>:180–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/9179740" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9179740</span></a>]<div>
|
||
<i>(At least one liver test abnormality was found in 60% of patients with hyperthyroidism before therapy; Alk P in 44% and ALT in 23%; often improving on propylthiouracil therapy, but 15% developed de novo ALT elevations by 6 weeks, although none were symptomatic, jaundiced or required dose modification).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.waseem.1998.197">Waseem M, Seshadri KG, Kabadi UM. Successful outcome with methimazole and lithium combination therapy for propylthiouracil-induced hepatotoxicity. <span><span class="ref-journal">Endocr Pract. </span>1998;<span class="ref-vol">4</span>:197–200.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15251733" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15251733</span></a>]<div>
|
||
<i>(49 year old man developed nausea 2 months after starting propylthiouracil; at 4 months bilirubin was 20.4 mg/dL, ALT 1043 U/L, Alk P 186 U/L, values worsening for 1 month despite stopping and then slowly returning towards normal despite use of methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.hung.1999.200">Hung YT, Yu WK, Chow E. Delayed cholestatic hepatitis due to methimazole. <span><span class="ref-journal">Hong Kong Med J. </span>1999;<span class="ref-vol">5</span>:200–1.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/11821593" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11821593</span></a>]<div>
|
||
<i>(71 year old woman developed jaundice a few weeks after stopping a 5 month course of methimazole with prolonged jaundice [bilirubin 40 mg/dL, ALT 40 U/L, Alk P 600 U/L], with slow recovery over more than 6 months).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.babini.1999.209">Babini G, Gurioli L, Rizzi R, Bertello P. Appearance of severe jaundice after radiometabolical treatment of thyrotoxicosis. <span><span class="ref-journal">J Endocrinol Invest. </span>1999;<span class="ref-vol">22</span>:209–11.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/10219889" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10219889</span></a>]<div>
|
||
<i>(63 year old man developed jaundice 2 weeks after receiving radioactive iodine for toxic goiter [bilirubin 6.8 mg/dL, ALT 86, Alk P 426 U/L], worsening for 2 weeks and then slowly improving with methimazole therapy of the hyperthyroidism).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.woeber.2002.222">Woeber KA. Methimazole-induced hepatotoxicity. <span><span class="ref-journal">Endocr Pract. </span>2002;<span class="ref-vol">8</span>:222–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12467281" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12467281</span></a>]<div>
|
||
<i>(36 year old woman developed pruritus and jaundice 3 weeks after starting methimazole [bilirubin 12.1 rising to 25.8 mg/dL, ALT 127 U/L, Alk P 265 U/L], with slow recovery and Alk P abnormalities for ~12 months).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.kontoleon.2002.304">Kontoleon P, Ilias I, Koutras DA, Kontogiannis D, Papapetrou PD. Successful treatment with carbimazole of a hyperthyroid pregnancy with hepatic impairment after propylthiouracil administration: a case report. <span><span class="ref-journal">Clin Exp Obstet Gynecol. </span>2002;<span class="ref-vol">29</span>:304–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12635752" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12635752</span></a>]<div>
|
||
<i>(27 year old woman developed elevations in ALT [151 U/L], with normal bilirubin [0.5 mg/dL] after 12th week of pregnancy while on propylthiouracil, resolving within 10 days of switching to carbimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.russo.2004.1018">Russo MV, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. <span><span class="ref-journal">Liver Transpl. </span>2004;<span class="ref-vol">10</span>:1018–23.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/15390328" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15390328</span></a>]<div>
|
||
<i>(Among 2291 liver transplants for acute liver failure done in the US between 1990 and 2002, 357 were attributed to medications, 53% to acetaminophen; in remaining 137 cases, most common agents were isoniazid [24; 17.5%], propylthiouracil [13; 9.5%], phenytoin [10; 7.3%], valproate [10; 7.3%], nitrofurantoin [7; 5%], herbals [7; 5%], ketoconazole [6; 4%] and disulfiram [6; 4%]; none due to methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.mikhail.2004.178">Mikhail NE. Methimazole-induced cholestatic jaundice. <span><span class="ref-journal">South Med J. </span>2004;<span class="ref-vol">97</span>:178–82.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/14982270" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14982270</span></a>]<div>
|
||
<i>(43 year old woman developed jaundice and pruritus one month after starting methimazole [bilirubin 16.7 mg/dL, ALT 104 U/L, Alk P 289 U/L], resolving 4 months after stopping; review of literature found 20 cases, 18 in women, onset in 3 days to 3 months, largely cholestatic, no fatalities from liver disease, recurrence on rechallenge with methimazole or carbimazole: Case 1).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.pi_ero_madrona.2004.388">Piñero Madrona A, Pons Miñano JA, Madrid Conesa J, Parrilla Paricio P. <span><span class="ref-journal">Rev Clin Esp. </span>2004;<span class="ref-vol">204</span>:388.</span> [Methimazole hepatitis] Spanish. [<a href="https://pubmed.ncbi.nlm.nih.gov/15274789" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15274789</span></a>]<div>
|
||
<i>(46 year old woman with subclinical hyperthyroidism developed arthralgias and malaise 6 days after starting methimazole [ALT 1280 U/L, Alk P 520 U/L with normal bilirubin], resolving within 2 weeks of stopping).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.casallo_blanco.2007.268">Casallo Blanco S, Valero MA, Marcos Sánchez F, de Matías Salces L, Blanco González JJ, Martín Barranco MJ. <span><span class="ref-journal">Gastroenterol Hepatol. </span>2007;<span class="ref-vol">30</span>:268–70.</span> [Methimazole and propylthiouracil induced acute toxic hepatitis] Spanish. [<a href="https://pubmed.ncbi.nlm.nih.gov/17493435" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17493435</span></a>]<div>
|
||
<i>(79 year old woman developed jaundice 1 month after starting methimazole [bilirubin 3.2 mg/dL, ALT 184 U/L, Alk P 574 U/L], with prompt improvement on stopping; then, 2 weeks after starting propylthiouracil, she redeveloped jaundice [bilirubin 5.5 mg/dL, ALT 448 U/L, Alk P 279 U/L], values normalizing within 2 months of stopping and with concurrent prednisone therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.ramosbonner.2007.236">Ramos-Bonner LS, Goldberg TH, Moyer S, Anastasopoulou C. Methimazole-induced cholestatic jaundice in an elderly hyperthyroid patient. <span><span class="ref-journal">Am J Geriatr Pharmacother. </span>2007;<span class="ref-vol">5</span>:236–40.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17996663" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17996663</span></a>]<div>
|
||
<i>(76 year old woman developed jaundice and pruritus 6 weeks after starting methimazole [bilirubin 25.4 mg/dL, ALT 676 U/L, Alk P 620 U/L, INR 1.2], worsening for 5 days and then resolving slowly).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Rochon J., Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18955056" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div>
|
||
<i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, none were attributed to propylthiouracil or methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.cooper.2009.1881">Cooper DS, Rivkees SA. Putting propylthiouracil in perspective. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2009;<span class="ref-vol">94</span>:1881–2.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19401361" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19401361</span></a>]<div>
|
||
<i>(Editorial summarizing issues of hepatotoxicity of propylthiouracil, 33 publications of hepatotoxicity in adults and 14 in children with UNOS reporting 16 liver transplants for acute liver failure due to propylthiouracil in adults and 7 in children between 1990 and 2007. In contrast, methimazole can cause liver injury but fatalities are rare; these factors led to recommendations that methimazole be used instead of propylthiouracil, except in first trimester of pregnancy [or for intolerance], and when surgery or radioiodine are not an option).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.bahn.2009.673">Bahn RS, Burch HS, Cooper DS, Garber JF, Greenlee CM, Klein IL, et al. The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. <span><span class="ref-journal">Thyroid. </span>2009;<span class="ref-vol">19</span>:673–4.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19583480" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19583480</span></a>]<div>
|
||
<i>(In 2008, propylthiouracil was prescribed for 101,000 persons in the US, while UNOS has reported 16 liver deaths in adults and 7 in children from propylthiouracil since 1990; making the estimated fatality rate from acute liver failure due to propylthiouracil 1:10,000 in adults and as high as 1:2000 in children; for these reasons, propylthiouracil should not be considered the “first line” of treatment of Graves disease, methimazole being preferred except in first trimester of pregnancy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.rivkees.2009.132041">Rivkees SA, Mattison DR. Propylthiouracil (PTU) hepatotoxicity in children and recommendations for discontinuation of use. <span><span class="ref-journal">Int J Pediatr Endocrinol. </span>2009;<span class="ref-vol">2009</span>:132041. </span> [<a href="/pmc/articles/PMC2777303/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2777303</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19946400" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19946400</span></a>]<div>
|
||
<i>(Review of propylthiouracil induced liver injury; 29 cases reported in literature, 14 in children, 9 resulting in death [3 in children] and 3 in liver transplantation; in contrast, fatality or transplantation due to methimazole induced liver disease has not been reported; concluded that propylthiouracil should not be used as treatment of Graves disease in children).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.gallelli.2009.204">Gallelli L, Staltari O, Palleria C, De Sarro G, Ferraro M. Hepatotoxicity induced by methimazole in a previously healthy patient. <span><span class="ref-journal">Curr Drug Saf. </span>2009;<span class="ref-vol">4</span>:204–6.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19534646" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19534646</span></a>]<div>
|
||
<i>(54 year old man developed fever, rash and then jaundice arising 14 days after starting methimazole [bilirubin 4.4 mg/dL, ALT 55 U/L, Alk P 374 U/L, GGT 627 U/L], resolving rapidly with stopping methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.zhang.2010.241">Zhang M, Zhou H, He R, Di F, Yang L, Yang T. Steroids for the treatment of methimazole-induced severe cholestatic jaundice in a 74-year-old woman with type 2 diabetes. <span><span class="ref-journal">Endocrine. </span>2010;<span class="ref-vol">37</span>:241–3.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20960257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20960257</span></a>]<div>
|
||
<i>(74 year old woman developed jaundice and pruritus 1 month after starting methimazole [bilirubin 14.9 mg/dL, ALT 92 U/L, Alk P 301 U/L], resolving slowly and with 8 weeks of prednisone).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.livadas.2010.24">Livadas S, Xyrafis X, Economou F, Boutzios G, Christou M, Zerva A, Karachalios A, Palioura H, Palimeri S, Diamanti-Kandarakis E. Liver failure due to antithyroid drugs: report of a case and literature review. <span><span class="ref-journal">Endocrine. </span>2010;<span class="ref-vol">38</span>:24–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20960098" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20960098</span></a>]<div>
|
||
<i>(34 year old woman developed pruritus 20 days after starting methimazole [bilirubin 2.4 rising to 3.6 mg/dL, ALT 141 to 1125 U/L, Alk P 189 to 396 U/L], resolving within 4 weeks of stopping).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.shen.2010.93">Shen C, Zhao CY, Liu F, Wang YD, Yu J. Acute-on-chronic liver failure due to thiamazole in a patient with hyperthyroidism and trilogy of Fallot: case report. <span><span class="ref-journal">BMC Gastroenterol. </span>2010;<span class="ref-vol">10</span>:93.</span> [<a href="/pmc/articles/PMC2928759/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2928759</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20707932" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20707932</span></a>]<div>
|
||
<i>(24 year old man developed jaundice 1 year after starting methimazole [bilirubin 34.3 mg/dL, ALT 75 U/L, Alk P 133 U/L, INR 2.3], with progression to hepatic failure and death 27 days after presentation).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.alvarez.2010.451">Alvarez MP, Cano RL, Fernández CP, Méndez LF, García RG. <span><span class="ref-journal">Endocrinol Nutr. </span>2010;<span class="ref-vol">57</span>:451–3.</span> [Acute toxic hepatitis induced by methimazole: two cases] Spanish. [<a href="https://pubmed.ncbi.nlm.nih.gov/20675204" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20675204</span></a>]<div>
|
||
<i>(Two cases; 71 and 52 year old women developed enzyme elevations 6 weeks after starting methimazole [bilirubin 0.8 and 0.9 mg/dL, ALT 102 and 546 U/L, Alk P 889 and 999 U/L], resolving within 2 and 4 months of stopping).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.rivkees.2010.3260">Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010;<span class="ref-vol">95</span>:3260–7.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/20427502" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20427502</span></a>]<div>
|
||
<i>(Analysis of FDA adverse event reports between 1969 and 2008 showed a higher rate of severe liver injury due to propylthiouracil than methimazole in children; “We are unaware of reports of death and liver failure in children and adolescents taking methimazole”).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.malozowski.2010.3161">Malozowski S, Chiesa A. Propylthiouracil-induced hepatotoxicity and death. Hopefully, never more. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2010;<span class="ref-vol">95</span>:3161–3.</span> [<a href="/pmc/articles/PMC2928912/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2928912</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20610609" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20610609</span></a>]<div>
|
||
<i>(Editorial in response to Rivkees [2010] summarizing the factors that led to the recommendation that propylthiouracil be avoided in children and be considered a second line drug for treating hyperthyroidism in adults).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20949552" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div>
|
||
<i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury including 5 due to propylthiouracil, but none to methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.sato.2011.257">Sato H, Minagawa M, Sasaki N, Sugihara S, Kazukawa I, Minamitani K, Wataki K, et al. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome. <span><span class="ref-journal">J Pediatr Endocrinol Metab. </span>2011;<span class="ref-vol">24</span>:257–63.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/21823520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 21823520</span></a>]<div>
|
||
<i>(Retrospective analysis of safety and efficacy of methimazole in 64 and propylthiouracil in 69 children with hyperthyroidism found similar response rates, but more frequent adverse events with initial high doses of propylthiouracil).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.yang.2012.2189">Yang J, Zhong J, Zhou LZ, Hong T, Xiao XH, Wen GB. Sudden onset agranulocytosis and hepatotoxicity after taking methimazole. <span><span class="ref-journal">Intern Med. </span>2012;<span class="ref-vol">51</span>:2189–92.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22892501" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22892501</span></a>]<div>
|
||
<i>(38 year old woman with hyperthyroidism developed agranulocytosis and liver test abnormalities within a week of starting methimazole [bilirubin 1.5 mg/dL, ALT 226 U/L, Alk P 143], resolving within a week of stopping methimazole and starting G-CSF).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.hackmon.2012.1077">Hackmon R, Blichowski M, Koren G. The safety of methimazole and propylthiouracil in pregnancy: a systematic review. <span><span class="ref-journal">J Obstet Gynaecol Can. </span>2012;<span class="ref-vol">34</span>:1077–86.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23231846" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23231846</span></a>]<div>
|
||
<i>(Systematic review of safety of propylthiouracil and methimazole during pregnancy concludes that propylthiouracil "has been associated with a rare but serious form of hepatic failure").</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.otsuka.2012.310">Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Ito K, Taniyama M. Hepatotoxicity and cutaneous reactions after antithyroid drug administration. <span><span class="ref-journal">Clin Endocrinol (Oxf). </span>2012;<span class="ref-vol">77</span>:310–5.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22332800" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22332800</span></a>]<div>
|
||
<i>(Among 391 patients with hyperthyroidism, ALT levels >2 times ULN occurred in 9% on methimazole vs 26% on propylthiouracil arising after 12 to 60 days, but "...no serious liver failure was observed").</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.kwon.2012.268">Kwon H, Lee SH, Kim SE, Lee JH, Jee YK, Kang HR, Park BJ, Park JW, Hong CS. Spontaneously reported hepatic adverse drug events in Korea: multicenter study. <span><span class="ref-journal">J Korean Med Sci. </span>2012;<span class="ref-vol">27</span>:268–73.</span> [<a href="/pmc/articles/PMC3286773/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3286773</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22379337" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22379337</span></a>]<div>
|
||
<i>(Summary of 2 years of adverse event reporting in Korea; of 9360 reports, 567 were liver related, including two attributed to propylthiouracil, but none to methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.maci_bobes.2012.431">Maciá-Bobes C, Ronzón-Fernández A, Macías-Robles MD, Fau-Cubero C. <span><span class="ref-journal">Farm Hosp. </span>2012;<span class="ref-vol">36</span>:431–2.</span> [Methimazole-induced liver injury] Spanish. [<a href="https://pubmed.ncbi.nlm.nih.gov/22857866" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22857866</span></a>]<div>
|
||
<i>(75 year old woman with toxic nodular goiter and multiple drug allergies developed liver test abnormalities 6 weeks after starting methimazole [bilirubin normal, ALT 454 U/L, GGT 268 U/L, Alk P normal], resolving within a month of switching to carbimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.regelmann.2012.437">Regelmann MO, Miloh T, Arnon R, Morotti R, Kerkar N, Rapaport R. Graves disease presenting with severe cholestasis. <span><span class="ref-journal">Thyroid. </span>2012;<span class="ref-vol">22</span>:437–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22458973" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22458973</span></a>]<div>
|
||
<i>(17 year old girl with acute hepatitis A and Graves disease developed marked cholestasis, which improved with therapy of hyperthyroidism).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.yoshihara.2012.2396">Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, et al. Treatment of graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2012;<span class="ref-vol">97</span>:2396–403.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/22547422" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22547422</span></a>]<div>
|
||
<i>(Among 5997 infants of Japanese women with thyrotoxicosis during the first trimester, congenital malformations were found in 4.1% of infants of 1231 methimazole treated, 1.9% of 1399 propylthiouracil treated and 2.1% of 1906 untreated mothers).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.de_campos_mazo.2013.9">de Campos Mazo DF, de Vasconcelos GB, Pereira MA, de Mello ES, Bacchella T, Carrilho FJ, et al. Clinical spectrum and therapeutic approach to hepatocellular injury in patients with hyperthyroidism. <span><span class="ref-journal">Clin Exp Gastroenterol. </span>2013;<span class="ref-vol">6</span>:9–17.</span> [<a href="/pmc/articles/PMC3579408/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3579408</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23550044" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23550044</span></a>]<div>
|
||
<i>(Among 7 patients with hyperthyroidism found to have liver disease, 2 were attributed to propylthiouracil hepatotoxicity, 2 to autoimmune hepatitis and 3 to the underlying hyperthyroidism, but none to methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.korelitz.2013.758">Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA. Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. <span><span class="ref-journal">Thyroid. </span>2013;<span class="ref-vol">23</span>:758–65.</span> [<a href="/pmc/articles/PMC3675839/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3675839</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23194469" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23194469</span></a>]<div>
|
||
<i>(Analysis of 4902 15-44 year old women with thyrotoxicosis during pregnancy in a health insurance database [2005-2009] found no increase in liver abnormalities or congenital defects associated with either propylthiouracil or methimazole therapy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.andersen.2013.4373">Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. <span><span class="ref-journal">J Clin Endocrinol Metab. </span>2013;<span class="ref-vol">98</span>:4373–81.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24151287" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24151287</span></a>]<div>
|
||
<i>(In a population based cohort study from Denmark, exposure to either methimazole or propylthiouracil during pregnancy was associated with an increased rate of birth defects, but not use of these agents before or after pregnancy).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.bj_rnsson.2013.1419">Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/23419359" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div>
|
||
<i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to antithyroid medications).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.hern_ndez.2014.231">Hernández N, Bessone F, Sánchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al. Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/24552865" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div>
|
||
<i>(Among 176 reports of drug induced liver injury from Latin America published between 1996 and 2012, five [including 2 deaths] were attributed to propylthiouracil but none to methimazole).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.wang.2014.619">Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH. Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2014;<span class="ref-vol">78</span>:619–29.</span> [<a href="/pmc/articles/PMC4243912/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4243912</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25279406" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25279406</span></a>]<div>
|
||
<i>(Among 71,379 patients with hyperthyroidism initiating medical therapy between 2004 and 2009 identified in the Taiwanese National Health Insurance Research Database, methimazole/carbimazole had a higher rate of clinically apparent liver injury than propylthiouracil [3.2 vs 1.2] but a lower rate of acute liver failure [0.32 vs o.68: both per 1000-patient years]).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.akmal.2014.1397">Akmal A, Kung J. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2014;<span class="ref-vol">13</span>:1397–406.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25156887" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25156887</span></a>]<div>
|
||
<i>(Review of the hepatotoxicity of antithyroid medications concludes that methimazole and carbimazole are more likely to cause cholestatic liver injury, while propylthiouracil is more likely to cause acute liver failure for which reason its use should be limited to use in adults and in the first trimester of pregnancy and thyroid storm)</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.heidari.2014.237">Heidari R, Niknahad H, Jamshidzadeh A, Abdoli N. Factors affecting drug-induced liver injury: antithyroid drugs as instances. <span><span class="ref-journal">Clin Mol Hepatol. </span>2014;<span class="ref-vol">20</span>:237–48.</span> [<a href="/pmc/articles/PMC4197171/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4197171</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25320726" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25320726</span></a>]<div>
|
||
<i>(Review of risk factors associated with liver injury from methimazole and propylthiouracil including age, gender, alcohol use and co-morbidities, none of which appear to play a very major role).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.heidari.2015.1">Heidari R, Niknahad H, Jamshidzadeh A, Eghbal MA, Abdoli N. An overview on the proposed mechanisms of antithyroid drugs-induced liver injury. <span><span class="ref-journal">Adv Pharm Bull. </span>2015;<span class="ref-vol">5</span>:1–11.</span> [<a href="/pmc/articles/PMC4352210/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4352210</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25789213" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25789213</span></a>]<div>
|
||
<i>(Review of the possible mechanisms of liver injury due to methimazole and propylthiouracil).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.papachristos.2015">Papachristos DA, Huynh J, Grossman M, MacIsaac RJ. Liver dysfunction and anti-thyroid therapy. SAGE Open Med Case Rep 2015; 3: 2050313X14568335. [<a href="/pmc/articles/PMC4857332/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4857332</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27489677" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 27489677</span></a>]<div><i>(49 year old man with Graves disease developed jaundice 2 weeks after starting carbimazole [bilirubin 34 mg/dL, ALT 104 U/L, Alk P 147 U/L], which resolved within 3 months of stopping and after radioactive iodine treatment making it difficult to assess whether the injury was due to the medication versus hyperthyroidism).</i></div></div></li><li><div class="bk_ref" id="Methimazole.REF.yang.2015.278">Yang J, Li LF, Xu Q, Zhang J, Weng WW, Zhu YJ, Dong MJ. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. <span><span class="ref-journal">Thyroid. </span>2015;<span class="ref-vol">25</span>:278–83.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/25384184" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25384184</span></a>]<div>
|
||
<i>(Among 90 patients with hyperthyroidism and drug induced liver injury due to antithyroid therapy seen at a single medical center over a 13 year period, 51 were attributed to methimazole [1 fatal] and 39 to propylthiouracil [none fatal]; both had similar latencies to onset [80% within 3 months, 60% within 1 month] and methimazole cases were more likely to be cholestatic [35% vs 18%] and less likely hepatocellular [43% vs 56%]).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.chalasani.2015">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015; 148: 1340-52. e7. [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25754159" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 6 [0.7%] were attributed to antithyroid drugs including 3 to methimazole [thiamazole], all of which were cholestatic or mixed and self-limited in course, and 3 to propylthiouracil, one of which was fatal and one occurring in a woman treated during pregnancy).</i></div></div></li><li><div class="bk_ref" id="Methimazole.REF.ji.2017.e9093">Ji H, Yue F, Song J, Zhou X. A rare case of methimazole-induced cholestatic jaundice in an elderly man of Asian ethnicity with hyperthyroidism: A case report. <span><span class="ref-journal">Medicine (Baltimore). </span>2017;<span class="ref-vol">96</span>(49):e9093. </span> [<a href="/pmc/articles/PMC5728948/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5728948</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29245333" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29245333</span></a>]<div>
|
||
<i>(69 year old Asian man developed jaundice 3 weeks after starting methimazole for hyperthyroidism [bilirubin 21.6 mg/dL, ALT 59 U/L, Alk P 631 U/L], improving rapidly upon stopping).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.abramavicius.2017.e8159">Abramavicius S, Velickiene D, Kadusevicius E. Methimazole-induced liver injury overshadowed by methylprednisolone pulse therapy: Case report. <span><span class="ref-journal">Medicine (Baltimore). </span>2017;<span class="ref-vol">96</span>:e8159. </span> [<a href="/pmc/articles/PMC5626305/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5626305</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28953662" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28953662</span></a>]<div>
|
||
<i>(74 year old woman with Graves disease and ophthalmopathy on methimazole therapy developed elevated ALT and AST levels after a 5<sup>th</sup> weekly infusion of methylprednisolone, which gradually resolved despite continuing both drugs).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.forner.2017.143">Forner D, Kulai T, Arnason T, E, Gruchy S, MacLeod M. Ramipril-associated cholestasis in the setting of recurrent drug-induced liver injury. <span><span class="ref-journal">Gastroenterol Hepatol Bed Bench. </span>2017;<span class="ref-vol">10</span>:143–6.</span> [<a href="/pmc/articles/PMC5495903/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC5495903</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28702139" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28702139</span></a>]<div>
|
||
<i>(67 year old man had two episodes of suspected drug induced liver injury, one due to methimazole and another 20 years later to ramipril, both being cholestatic and self-limited in course).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.jin.2019.508">Jin S, Li X, Fan Y, Fan X, Dai Y, Lin H, Cai W, et al. Association between genetic polymorphisms of SLCO1B1 and susceptibility to methimazole-induced liver injury. <span><span class="ref-journal">Basic Clin Pharmacol Toxicol. </span>2019;<span class="ref-vol">125</span>:508–17.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31240859" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31240859</span></a>]<div>
|
||
<i>(Several polymorphisms of SLCOB1 [the gene that encodes the organic anion-transporting peptide B1] were found more frequent among 44 patients with Graves disease who developed methimazole induced liver injury than in 118 Graves disease patients who did not).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.li.2019.109095">Li X, Jin S, Fan Y, Fan X, Tang Z, Cai W, Yang J, et al. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. <span><span class="ref-journal">Biomed Pharmacother. </span>2019;<span class="ref-vol">117</span>:109095. </span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31202168" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31202168</span></a>]<div>
|
||
<i>(Analysis of HLA class I and II alleles in patients with Graves disease who developed methimazole hepatotoxicity [n=40] or not [n=118], the allele frequency of HLA-C*03.02 was 6.7% in patients with methimazole hepatotoxicity compared to 0.4% of those who tolerated the drug without liver injury).</i>
|
||
</div></div></li><li><div class="bk_ref" id="Methimazole.REF.suzuki.2019.1390">Suzuki N, Noh JY, Hiruma M, Kawaguchi A, Morisaki M, Ohye H, Suzuki M, et al. Analysis of antithyroid drug-induced severe liver injury in 18,558 newly diagnosed patients with Graves' disease in Japan. <span><span class="ref-journal">Thyroid. </span>2019;<span class="ref-vol">29</span>:1390–8.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/31573408" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31573408</span></a>]<div>
|
||
<i>(Among 18,558 Japanese patients initiating medical therapy of Graves disease between 2005 and 2017, 416 [2.5%] developed evidence of liver injury [ALT above 8 times ULN or bilirubin above 3 times ULN], 1.4% on methimazole and 6.3% of propylthiouracil, 92% were women, onset usually within 30 days, rates being age-dependent and all patients recovered).</i>
|
||
</div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
|
||
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548406</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31643725" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">31643725</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Methenamine/" title="Previous page in this title">< Prev</a><a class="active page_link next" href="/books/n/livertox/Methocarbamol/" title="Next page in this title">Next ></a></div></div></div></div>
|
||
|
||
</div>
|
||
</div>
|
||
</div>
|
||
<div class="bottom">
|
||
|
||
<div id="NCBIFooter_dynamic">
|
||
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
||
<component id="Breadcrumbs" label="helpdesk"/>-->
|
||
|
||
</div>
|
||
|
||
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
||
</div>
|
||
</div>
|
||
<!--/.page-->
|
||
</div>
|
||
<!--/.wrap-->
|
||
</div><!-- /.twelve_col -->
|
||
</div>
|
||
<!-- /.grid -->
|
||
|
||
<span class="PAFAppResources"></span>
|
||
|
||
<!-- BESelector tab -->
|
||
|
||
|
||
|
||
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK548406&ncbi_domain=livertox&ncbi_report=printable&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK548406/?report=printable&ncbi_app=bookshelf" /></noscript>
|
||
|
||
|
||
<!-- usually for JS scripts at page bottom -->
|
||
<!--<component id="PageFixtures" label="styles"></component>-->
|
||
|
||
|
||
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
||
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
||
|
||
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/3400083/3426610.js" snapshot="books"></script></body>
|
||
</html> |